Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Restructuring Costs: 2021-2023

Historic Restructuring Costs for Theravance Biopharma (TBPH) over the last 1 years, with Jun 2023 value amounting to $1.2 million.

  • Theravance Biopharma's Restructuring Costs fell 61.10% to $1.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $38.7 million, marking a year-over-year increase of 19.33%. This contributed to the annual value of $2.7 million for FY2023, which is 78.63% down from last year.
  • According to the latest figures from Q2 2023, Theravance Biopharma's Restructuring Costs is $1.2 million, which was down 25.73% from $1.6 million recorded in Q1 2023.
  • In the past 5 years, Theravance Biopharma's Restructuring Costs ranged from a high of $33.0 million in Q3 2022 and a low of $1.2 million during Q2 2023.
  • For the 3-year period, Theravance Biopharma's Restructuring Costs averaged around $9.7 million, with its median value being $3.0 million (2022).
  • Its Restructuring Costs has fluctuated over the past 5 years, first surged by 1,763.35% in 2022, then crashed by 83.12% in 2023.
  • Over the past 3 years, Theravance Biopharma's Restructuring Costs (Quarterly) stood at $18.4 million in 2021, then soared by 1,763.35% to $33.0 million in 2022, then tumbled by 61.10% to $1.2 million in 2023.
  • Its Restructuring Costs stands at $1.2 million for Q2 2023, versus $1.6 million for Q1 2023 and $33.0 million for Q3 2022.